Anthem Biosciences is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing.

Anthem Biosciences major competitors are Syngene Internation., Sai Life Sciences, Cohance Lifesciences, Akums Drugs & Pharma, Divi's Lab.
Market Cap of Anthem Biosciences is ₹45,763 Crs.
While the median market cap of its peers are ₹25,591 Crs.

Anthem Biosciences seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.